Sun Pharma to Acquire Organon in Transformative $11.75 Billion Deal Focused on Women’s Health
Sun Pharma has announced a landmark definitive agreement to acquire Organon in an all-cash transaction valued at approximately $11.75 billion, marking one of the...
Novartis Receives European Commission Approval for Rhapsido®, the First Oral Targeted Therapy for Chronic Spontaneous Urticaria
Novartis has officially received European Commission (EC) approval for Rhapsido® (remibrutinib), marking a historic shift in the management of chronic spontaneous urticaria (CSU). Rhapsido...
A Global Pediatric Milestone: WHO Pre qualifies First Malaria Treatment for Newborns and Young Infants
In a landmark step for global child health, the World Health Organization (WHO) has prequalified the world’s first malaria treatment specifically designed for newborns...
AbbVie Moves Toward “Fast-Acting” Botox Alternative: FDA Requests Final Manufacturing Details for 24-Hour Frown Line Treatment
AbbVie is set to rewrite the timeline of aesthetic medicine, as it received the receipt of a Complete Response Letter (CRL) from the...
Johnson & Johnson to Acquire Atraverse Medical to Expand Cardiac Care Portfolio
Johnson & Johnson has entered into a definitive agreement to acquire Atraverse Medical, a medical device innovator focused on left-heart access technologies. The move...
New Hope for MOGAD Patients: ENSPRYNG Demonstrates Unparalleled 68% Reduction in Disabling Relapses
The Phase III METEOROID study, revealed ENSPRYNG (satralizumab) showing reduction in the risk of relapses by 68% in patients compared to placebo,according to...